Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

The efficacy and toxicity of the PARP inhibitor parthanatine, radiolabeled with the alpha particle emitter astatine-211, in 11 patient derived neuroblastoma murine xenografts is investigated.

Bibliographic Details
Main Authors: Mehran Makvandi, Minu Samanta, Paul Martorano, Hwan Lee, Sarah B. Gitto, Khushbu Patel, David Groff, Jennifer Pogoriler, Daniel Martinez, Aladdin Riad, Hannah Dabagian, Michael Zaleski, Tara Taghvaee, Kuiying Xu, Ji Youn Lee, Catherine Hou, Alvin Farrel, Vandana Batra, Sean D. Carlin, Daniel J. Powell, Robert H. Mach, Daniel A. Pryma, John M. Maris
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-022-04209-8

Internet

https://doi.org/10.1038/s42003-022-04209-8

Similar Items